Bioavailability Enhancement

:: Overview :: Poorly Soluble Drugs :: Poorly Permeable Drugs


Pharmaterials proprietary IntraSOLV™ technology optimises the delivery of drugs that are poorly absorbed due to their inherent solubility problems. By optimising the therapeutic performance of these types of drugs with IntraSOLV™, Pharmaterials offers numerous opportunities to its partners to rescue new chemical entities and provide better medicines to their customers.

The basis for IntraSOLV™ is that the 'apparent' solubility of nanocrystalline and amorphous compounds are higher than those of unmodified or even micronized forms. Therefore, absorption rate and absolute bioavailability of the drug can be increased if drug permeability is sufficient. A poorly soluble, yet permeable crystalline drug is considered activated when it undergoes a change in its physical state that improves its biopharmaceutical properties.

Advantages of the IntraSOLV™ approach include:

• Novel polymeric matrix which increases the stability of the drug in a molecularly dispersed or amorphous state, preventing crystallisation during storage
• Improved binding between the drug and polymer matrix gives increased drug loading without compromising stability
• Suitable for capsule filling or tableting
• Can be easility manufactured with conventional solids-processing equipment